NO20063843L - Polymorfe formar av en GABA-A-agonist - Google Patents
Polymorfe formar av en GABA-A-agonistInfo
- Publication number
- NO20063843L NO20063843L NO20063843A NO20063843A NO20063843L NO 20063843 L NO20063843 L NO 20063843L NO 20063843 A NO20063843 A NO 20063843A NO 20063843 A NO20063843 A NO 20063843A NO 20063843 L NO20063843 L NO 20063843L
- Authority
- NO
- Norway
- Prior art keywords
- gaba
- agonist
- polymorphic forms
- new crystalline
- anhydrates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
To nye, krystallinske mono-hydrater og to nye, krystallinske anhydrater av gaboksadol er beskrevet, sammen med fiemgangsmåter for fremstilling av disse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
PCT/GB2005/000288 WO2005073237A2 (en) | 2004-01-30 | 2005-01-28 | Polymorphic forms of a gabaa agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063843L true NO20063843L (no) | 2006-08-29 |
Family
ID=31971783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063843A NO20063843L (no) | 2004-01-30 | 2006-08-29 | Polymorfe formar av en GABA-A-agonist |
Country Status (35)
Country | Link |
---|---|
US (2) | US7262300B2 (no) |
EP (2) | EP2042505A1 (no) |
JP (1) | JP4917440B2 (no) |
KR (1) | KR101210361B1 (no) |
CN (1) | CN1914212B (no) |
AR (1) | AR047511A1 (no) |
AT (1) | ATE414088T1 (no) |
AU (1) | AU2005209473B2 (no) |
BR (1) | BRPI0506858A (no) |
CA (1) | CA2554536C (no) |
CO (1) | CO5700743A2 (no) |
CY (1) | CY1108647T1 (no) |
DE (1) | DE602005010975D1 (no) |
DK (1) | DK1713813T3 (no) |
DO (1) | DOP2005000013A (no) |
EA (1) | EA009413B1 (no) |
EC (1) | ECSP066735A (no) |
ES (1) | ES2314613T3 (no) |
GB (2) | GB0402118D0 (no) |
HK (1) | HK1096547A1 (no) |
HR (1) | HRP20080614T3 (no) |
IL (1) | IL176863A0 (no) |
MA (1) | MA28364A1 (no) |
MX (1) | MXPA06008595A (no) |
MY (1) | MY139525A (no) |
NO (1) | NO20063843L (no) |
NZ (1) | NZ548191A (no) |
PE (1) | PE20050769A1 (no) |
PL (1) | PL1713813T3 (no) |
PT (1) | PT1713813E (no) |
SI (1) | SI1713813T1 (no) |
TW (1) | TWI345972B (no) |
UA (1) | UA87487C2 (no) |
WO (1) | WO2005073237A2 (no) |
ZA (1) | ZA200605307B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
EP1848420A4 (en) * | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
DK1928405T3 (da) | 2005-09-28 | 2014-12-15 | Auris Medical Ag | Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser |
CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
ES2862673T3 (es) | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
PE20190338A1 (es) * | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
AU2018309049A1 (en) | 2017-08-04 | 2020-02-27 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
US4315934A (en) | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
AU7405000A (en) | 1999-09-28 | 2001-04-30 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
EP1399138B1 (de) | 2001-05-18 | 2006-02-08 | Lonza Ag | Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat |
AU2002338855B2 (en) | 2001-05-21 | 2007-08-16 | H. Lundbeck A/S | Granular preparations of gaboxadol |
CN100491366C (zh) * | 2002-09-03 | 2009-05-27 | 华晶基因技术有限公司 | 汉黄芩素用作治疗焦虑症的药物的用途 |
DE602004025808D1 (de) * | 2003-06-25 | 2010-04-15 | Lundbeck & Co As H | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
AR045540A1 (es) * | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
WO2005023256A1 (en) | 2003-09-10 | 2005-03-17 | Merck Sharp & Dohme Limited | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
EA200700102A1 (ru) | 2004-06-29 | 2007-06-29 | Х.Лундбекк А/С | Лечение невропатической боли, фибромиалгии или ревматоидного артрита |
GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
WO2006102093A1 (en) | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
US20080262029A1 (en) | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 US US11/045,768 patent/US7262300B2/en active Active
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en active Active
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de active Active
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en active Search and Examination
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja active Active
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es active Active
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh active Active
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active IP Right Cessation
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-02-23 HK HK07102068A patent/HK1096547A1/xx unknown
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-11-26 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063843L (no) | Polymorfe formar av en GABA-A-agonist | |
DK1888580T3 (da) | Pyrido[2,3-D]pyrimidiner, der er egnede som HCV-hæmmere, og fremgangsmåde til fremstillingen af disse | |
NO20084777L (no) | Trinnvise sementeringsfremgangsmater som brukes ved samtidig boring og fôring | |
SG156689A1 (en) | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate | |
DK1698630T3 (da) | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater | |
EP1953542A4 (en) | METHOD FOR QUANTITATING A MEMBRANE PROTEIN USING A MASS SPECTROMETER | |
SG148142A1 (en) | Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof | |
NO20081926L (no) | Oppslemmingsblanding og fremgangsmåter for fremstilling av denne | |
NO20080784L (no) | Histondeacetylaseinhibitorer | |
DK1984744T3 (da) | Fremgangsmåder og sæt til diagnostisering af væksthormonmangel | |
ATE495162T1 (de) | Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung | |
BRPI0903495A2 (pt) | microorganismos mutantes com capacidade de produzir putrescina e método para produção de putrescina utilizando os mesmos | |
NO20065179L (no) | Polysykliske pyridiner som kalsium-kanalmodulatorer | |
NO20050235D0 (no) | System og fremgangsmate for produksjon til havs med bronnstyring | |
MX2009011255A (es) | Proceso para preparar capecitabina. | |
DK1924585T3 (da) | Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat | |
NO20051393L (no) | Prosess og intermediater for fremstilling av tienopyrrol-derivater | |
EP1856297A4 (en) | METHOD OF DETECTING CLASSIC PORCINE FEVER | |
ATE541853T1 (de) | Tanaproget-derivate, metaboliten und verwendungen dafür | |
DK1735623T3 (da) | Test til diagnosticering af infektion med mycobakterium tuberculosis | |
DK1994005T3 (da) | Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere | |
WO2007075307A3 (en) | Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate | |
GT200500216A (es) | Derivados de cci-779 y metodos para su preparacion | |
ATE458196T1 (de) | Verfahren zum apoptosenachweis | |
NO20083269L (no) | Prosess for a anvende krystallinsk orlistatmetoder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |